Nicole L. Stone

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

23h-index4.8kcitations56works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(18), Bladder and Urothelial Cancer Treatments(12), Chronic Lymphocytic Leukemia Research(7), Blood properties and coagulation(6), Urinary and Genital Oncology Studies(6)

Publications55 total

A real-world evidence study assessing the prevalence of FGFR alterations in patients with non-muscle invasive bladder cancer, as defined by the international bladder cancer group
European Urology Open Science·2025Open Access
1766eP Deep learning-based digital pathology algorithm overcomes tumor content limitations for FGFR alteration detection in non-muscle invasive bladder cancer
Annals of Oncology·2025
Inferring FGFR status from H&E images using digital pathology to identify patients for early-stage bladder cancer targeted therapies.
Journal of Clinical Oncology·2025
Artificial intelligence-augmented drug discovery identifies gefitinib as a potential treatment for ALS
2025Open Access
A0673 – A real-world evidence study evaluating the prevalence of FGFR alterations in patients with intermediate risk non-muscle invasive bladder cancer, as defined by the International Bladder Cancer Group (IBCG)
European Urology·2025
MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER
Urologic Oncology Seminars and Original Investigations·2025· 1 cited
O01 First-in-human study of TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
European Urology Open Science·2024Open Access
1973P Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210
Annals of Oncology·2024Open Access
Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial
Nature Communications·2024· 23 citedOpen Access
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).
Journal of Clinical Oncology·2024· 1 cited
PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT <i>FGFR</i> ALTERATIONS
The Journal of Urology·2024· 6 cited
First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
European Urology·2024· 3 cited
Urine-based testing for patient selection and genomic characterization of patients with <i>FGFR</i> alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.
Journal of Clinical Oncology·2024· 1 cited
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine·2023· 257 cited
Implication of the Autophagy-Related Protein Beclin1 in the Regulation of EcoHIV Replication and Inflammatory Responses
UNC Libraries·2023Open Access
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Annals of Oncology·2023· 28 citedOpen Access
Implication of the Autophagy-Related Protein Beclin1 in the Regulation of EcoHIV Replication and Inflammatory Responses
Viruses·2023· 8 citedOpen Access
Generalizable FGFR prediction across tumor types using self supervised learning.
Journal of Clinical Oncology·2023· 2 cited
Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select <i>FGFR</i> mutations or fusions: Phase 1 first-in-human study.
Journal of Clinical Oncology·2023· 13 cited
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
Prostate Cancer and Prostatic Diseases·2021· 31 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

James B. Bussel(11), Gregory Cheng(11), Mansoor N. Saleh(11), Bhabita Mayer(9), Neil Beeharry(9), M. Arning(7), Manuel Aivado(6), Saoirse E. O’Sullivan(6), Ja Hyeon Ku(6), Spyros Triantos(6), Gautam Jayram(6), Anna Kalota(6), Josh Lauring(6), Bethan Psaila(5), J.M. Jenkins(5), Sandra Y. Vasey(5), Antoni Vilaseca(5), Neal D. Shore(5), Daniel Zainfeld(5), Joshua J. Meeks(5)